Continuous WNT Control Enables Advanced hPSC Cardiac Processing and Prognostic Surface Marker Identification in Chemically Defined Suspension Culture

Caroline Halloin,1,5 Kristin Schwanke,1,5 Wiebke Löbel,1 Annika Franke,1 Monika Szepes,1 Santoshi Biswanath,1 Stephanie Wunderlich,1 Sylvia Merkert,1 Natalie Weber,2 Felix Osten,2 Jeanne de la Roche,3 Felix Polten,4 Kai Wollert,4 Theresia Kraft,2 Martin Fischer,3 Ulrich Martin,3 Ina Gruh,1 Henning Kempf,1,5,6,* and Robert Zweigerdt1,5,*

1Leibniz Research Laboratories for Biotechnology and Artificial Organs (LEBAO), Department of Cardiac, Thoracic-, Transplantation and Vascular Surgery, REBIRTH-Cluster of Excellence, Hannover Medical School, Carl-Neuberg-Strasse 1, 30625 Hannover, Germany
2Institute of Molecular and Cell Physiology, Hannover Medical School, Carl-Neuberg-Strasse 1, 30625 Hannover, Germany
3Institute for Neurophysiology, Hannover Medical School, Carl-Neuberg-Strasse 1, 30625 Hannover, Germany
4Division of Molecular and Translational Cardiology and Department of Cardiology and Angiology, Hannover Medical School, Carl-Neuberg-Strasse 1, 30625 Hannover, Germany
5Co-first author
6Present address: Department of Stem Cell Biology, Novo Nordisk A/S, 2760 Maaloev, Denmark
*Correspondence: henningkempf@outlook.com (H.K.), zweigerdt.robert@mh-hannover.de (R.Z.)

SUMMARY

Aiming at clinical translation, robust directed differentiation of human pluripotent stem cells (hPSCs), preferentially in chemically defined conditions, is a key requirement. Here, feasibility of suspension culture based hPSC-cardiomyocyte (hPSC-CM) production in low-cost, xeno-free media compatible with good manufacturing practice standards is shown. Applying stirred tank bioreactor systems at increasing dimensions, our advanced protocol enables routine production of about 1 million hPSC-CMs/mL, yielding ∼1.3 × 10^8 CM in 150 mL and ∼4.0 × 10^8 CMs in 350–500 mL process scale at >90% lineage purity. Process robustness and efficiency is ensured by uninterrupted chemical WNT pathway control at early stages of differentiation and results in the formation of almost exclusively ventricular-like CMs. Modulated WNT pathway regulation also revealed the previously unappreciated role of ROR1/CD13 as superior surrogate markers for predicting cardiac differentiation efficiency as soon as 72 h of differentiation. This monitoring strategy facilitates process upscaling and controlled mass production of hPSC derivatives.

INTRODUCTION

Progress in human pluripotent stem cell (hPSC) research has the potential to revolutionize regenerative medicine. Functional hPSC progenies may either fuel advanced in vitro assays for better drug development or replenish the loss of functional cells in diseased organs.

Given the high incidence of cardiac disorders, there have been substantial efforts in investigating cardiomyogenic differentiation of hPSCs. Stages of differentiation include early mesendodermal priming (Kempf et al., 2016), specification of cardiac progenitors (Soh et al., 2016), and directed differentiation into cardiomyocyte (CM) subtypes such as ventricular-, atrial- and nodal-like phenotypes (Devalia et al., 2015; Protze et al., 2017). Process specification was also accompanied by revealing more lineage-specific surface markers facilitating monitoring of differentiation stages and process optimization (reviewed in Skelton et al., 2017).

The field has also progressed from using recombinant factors toward chemical compounds for directing CM induction. These protocols typically aim at mimicking the biphasic pattern of WNT pathway upregulation and subsequent attenuation known from early heart development (Gonzalez et al., 2011; Lian et al., 2012; Tran et al., 2009; Ueno et al., 2007). Notably, chemical WNT pathway stimulators (particularly the GSK3 inhibitor CHIR99021 [CHIR]) or suppressors (including IWP2, IWR1, and Wnt-C59) have also been applied to specify other mesendodermal lineages including hepatocytes (Siller et al., 2015) and skeletal muscle cells (Shelton et al., 2014). This highlights process complexity due to the multiple spatio-temporally dependent roles of the WNT pathway in development. Moreover, we have recently demonstrated that, in response to CHIR stimulation, a complex pattern of paracrine factors, whose feedback-controlled concentration depends on the applied cell density, substantially modulates early primitive streak (PS)-like priming (Gaspari et al., 2018; Kempf et al., 2016). Thus, in addition to the well-studied impact of the CHIR dose, the cell density and the exact process timing have a dominant impact on hPSC differentiation.

Cell production in suspension culture by the differentiation of matrix-free hPSC aggregates is more compatible with process upscaling. It facilitates transition to stirred tank bioreactors favored for process control and
optimization for conventional mammalian cell lines in the biotech industry. We and others demonstrated feasibility of suspension culture for both hPSC expansion (Abecasis et al., 2017; Kropp et al., 2016) and lineage differentiation, including successful CM, endothelial cell, and macrophage production (Ackermann et al., 2015; Fonoudi et al., 2015; Kempf et al., 2014; Olmer et al., 2018). However, whereas two-dimensional (2D) culture is restricted in their complexity, the number of process variables increases in 3D suspension culture. Besides the overall cell density, spherical aggregates (3D) increase in size over time (4D), thus constantly changing the physical and physiological parameters of the culture.

Multidimensional process parameters in combination with the known hPSC line-dependent properties often result into interexperimental variability. We have reported, for example, the average induction of ~80% CMs in stirred suspension, but noted process variability ranging from <60% to >90% CM content (Kempf et al., 2014).

We thus performed systematic modifications of process parameters in this study by applying several culture platforms and numerous hPSC lines. By focusing on the critical early steps particularly on hPSC aggregation and the timing of chemical WNT modulation, a more robust and efficient protocol was developed. This includes the systematic usage of chemically defined media compatible with large-scale cell production and transition to good manufacturing practice standards. Applying molecular cell analysis in response to process modifications a novel surface marker, ROR1, is revealed which, in combination with CD13, is superior for predictive monitoring of cardiac mesoderm formation.

RESULTS

WNT Pathway Inhibition Improves Priming toward Cardiac Mesoderm

After kick-starting cardiac differentiation by 24 h of CHIR supplementation, WNT pathway attenuation is typically initiated after a 48- to 72-h gap (Kempf et al., 2014; Lian et al., 2012). In contrast to CHIR treatment, temporal patterning of WNT inhibition was less systematically investigated, particularly in suspension culture. We thus compared the effect of early (days 1–3) with that of the commonly applied late (days 3–5) supplementation of WNT inhibitors (schematic in Figure 1A). Flow cytometry (FC)-based endpoint analysis for CM-specific markers including cardiac troponin T (cTNT), sarcomeric actinin (SA), and myosin heavy chain (MHC) on day 10 revealed only low CM induction of ~15%–18% (HES3) and <1.5% (HSC-iPS2), respectively (Figures 1B and S1A), when the WNT antagonist IWP2 was added on day 3. In contrast, starting inhibition on day 1 (i.e., immediately after CHIR removal) resulted in >75% CM content for both cell lines and all markers tested (Figure 1B). This was confirmed by qRT-PCR (Figure S1D) and immune cytology-based analysis of suspension-derived, plated cells (Figure 1C).

Global gene expression analysis was conducted on day 0, day 1, and day 3 using HES3 (bright color code in Figure 1D) and HSC_iPS2 cells treated with (green dots) or without (gray dots) IWP2 on days 1–3 (Figure 1D). Principal component analysis showed expected clustering of day-0, -1, and -3 samples (Figures 1D and S1C). Notably, day-3 samples receiving no IWP2 (gray) appeared more distant to day 1 along the PC1 axis compared with IWP2-treated cells (green). This indicates that the (differentiation-induced) changes were less pronounced when IWP2 was supplemented, suggesting containment of differentiation progression by the inhibitor.

Interestingly, early WNT pathway inhibition appears to be essential to direct certain hPSC lines such as HSC_iPS2 toward the cardiomyogenic lineage, whereas the HES3 line seems to be less sensitive to external WNT inhibitors, in line with previous work (Kempf et al., 2014).

Gene ontology (GO) analysis of >10-fold regulated gene sets revealed that IWP2 treatment induced significant upregulation of genes related to the GO terms heart development and morphogenesis, while downregulated genes were associated with development and morphogenesis of the skeletal system, cartilage, bone, and cartilage, all resembling paraxial mesoderm derivatives (Figure S1B).

Patterning into cardiac versus presumptive presomitic mesoderm was confirmed by targeted heatmap analysis for associated GO terms, including osteoblast, skeletal muscle, mesenchyme, somite, and limb development. Remarkably, day-3 analysis of IWP-treated cells showed robust upregulation of key cardiac progenitor markers including ISL1, GATA4, MEF2C, NXXK2-6 (Biben et al., 1998), FZD4 (Yoon et al., 2018), and FOXC1/2, as well as TTN and TNNI (Figure 1E). Conversely, markers described to inhibit cardiac mesoderm but to promote presomitic specification including CDX1/2 and MSX1/2 (Greber et al., 2010; Mendjan et al., 2014) were significantly upregulated in the absence of early IWP2 treatment (confirmed for CDX2 by FC; Figure S1E).

ROR1 Distinguishes Cardiac from Paraxial Mesoderm

Multiple surface markers were reported to identify cardiac mesoderm during hPSC differentiation. We evaluated expression of these markers in our 3D system regarding their ability to discriminate cardiac versus presomitic mesoderm on day 3 of differentiation on gene and protein levels. Most established markers showed only marginal or
low induction (KDR, CXCR4, and GYP A), while others were upregulated (PDGFRA, NCAM, CD13, and ROR2) but failed to discriminate between the two lineages (Figures 2A, 2B, S2A, and S2B). Interestingly, ROR1, in contrast to the structurally related protein ROR2 (60% homology in protein sequence), depicted significantly higher levels in cardiac compared with presomitic mesoderm (Figures 2A, 2B, S2A, and S2C). Studies in mice reported Ror2 expression throughout the entire PS (Matsuda et al., 2001) while recent data indicate distinct Ror1 expression in the anterior-to-mid PS only (Peng et al., 2016) (Figure 2C) suggesting a distinct role of Ror1 during mesendodermal patterning (note that T delineates the PS area of the epiblast of the gastrulating embryo; Figure 2C). Likewise, proteome data from human fetal tissues revealed prominent expression of ROR1 but not other established surface markers in the developing heart (Kim et al., 2014) (Figure 2D). Indeed, in contrast to the combination of CD13+/ROR2+ (r = 0.73), combining analysis of CD13+/ROR1+ by FC on day 3 and corresponding cardiomyocyte content on day 10 showed a more significant correlation (r = 0.9) (Figures 2E, 2F, and S2B), with CD13+ serving as panmesoderm marker to exclude the potential presence of pluripotent cells that also express ROR1 but lack CD13 (Figure S2A).

Taken together, these data revealed ROR1 as a marker for cardiac mesoderm which, in combination with CD13, enables early prediction of cardiac differentiation efficiency.

Cell-Line-Independent Cardiomyogenesis in Chemically Defined Media

Considering upscaling of CM production for clinical translation, the development of cost-efficient xeno-free processes is essential. Based on successful hPSC expansion
and maintenance of pluripotency in stirred suspension culture in chemically defined E8 (Chen et al., 2012; Kropp et al., 2016), it was applied to replace mTeSR used previously (Ludwig et al., 2006; Olmer et al., 2012; Silva et al., 2015) and in this work (Figures 1 and 2). For CM differentiation the chemically defined medium CDM3, recently established in 2D, was utilized (Burridge et al., 2014). Based on reports demonstrating the importance of the preculture strategy (Chen et al., 2015; Fonoudi et al., 2015; Kempf et al., 2014), we combined modified timing of aggregate generation in E8 with the improved WNT modulation described above. Aggregates were formed in E8 in stirred tank bioreactors for either 2 or 4 days before transition to either CDM3 or RPMI/B27 (routinely used previously by Kempf et al., 2014; Lian et al., 2012), and for differentiation in rotated Erlenmeyer flasks (schematic in Figure 3A).

An increase in average aggregate diameter from 128.5 ± 49.60 μm on day 2 to 203.2 ± 79.3 μm on day 4 was observed (Figure 3B and picture inset in Figure 3A) while the cell density increased by ~4-fold (0.49 ± 0.07 × 10^6 and 2.2 ± 0.4 × 10^6 cells/mL, respectively; Figure 3C). Dissolved oxygen (DO) and pH (Figure 3D) values were substantially lower for day 4 than for day 2, demonstrating that, in addition to the mere change in aggregate diameters (suggested to impact on differentiation; Chen et al., 2015; Fonoudi et al., 2015), numerous other physical and
physiological parameters that may impact on differentiation vary as well.

Cells’ sensitivity to WNT pathway stimulation may also depend on the applied media. The CHIR concentration previously optimized to 7.5 μM in mTeSR/RPMI/B27 was thus reinvestigated (Kempf et al., 2014). Twenty-four hours of CHIR treatment at 5, 7.5, or 10 μM, respectively was immediately replaced by IWP2 for 48 h (days 1–3), and NKX2.5-eGFP expression was monitored as CM surrogate marker on day 10. For day-2 aggregates in RPMI/B27, 31.6% ± 11.8% of NKX2.5-eGFP+ cells were observed at 5 μM CHIR and even lower values were found for 7.5 μM and 10 μM CHIR, respectively (Figure 3E). For day-4 aggregates, the amount of GFP-expressing cells was also highest at 5 μM CHIR but the overall values were lower compared with day-2 aggregates (Figure 3E). Differentiation in
CDM3 substantially improved NKX2.5-eGFP expression and was most robust combining E8-derived day-2 aggregates with 7.5 μM CHIR (83.8% ± 4.4%; Figure 3F). Day-2 aggregates outperformed day-4 cells over the entire CHIR range tested (Figure 3F).

This chemically defined protocol (equivalent to schematic in Figure 3A) was tested with several lines (HES3-NKX2.5, HSC_iPS2, and Phoenix) with day-2 aggregates following differentiation in flasks at 5 μM and 7.5 μM CHIR.

In contrast to HES3-NKX2.5, 5 μM CHIR was optimal for HSC_iPS2 and Phoenix, inducing 91% and 93.7% ± 3.6% CMs, respectively (Figure 4A). CHIR at 7.5 μM also resulted in substantially lower cell yield during subsequent differentiation (Figures 4B, S3A, and S3B), eventually preventing endpoint analysis of HSC_iPS2 progenies. On the other hand, at 5 μM CHIR treatment, robust CM yields were observed for all cell lines tested (Figure 4B) whereby HES3-NKX2.5 were, again, less sensitive to the applied CHIR dose. Taken together, these data revealed that 5 μM CHIR is most appropriate for our chemically defined cardiac differentiation protocol.

Additional human embryonic stem cell (hESC) and human iPSC (hiPSC) lines were assessed in a broadly available 6-well low-attachment platform revealing >70% CM induction across the seven cell lines tested (Figure 4C), supporting the general cell-line- and culture platform-independent utility of our protocol. Moreover, comparing the WNT pathway inhibitors IWP2 with Wnt-C59 using Phoenix showed comparable differentiation efficiencies (Figure 4D).

Process Upscaling in Stirred Tank Bioreactors Enables High Cell Yield at >90% CM Purity and Confirms Utility of CD13+/ROR1+ for Early Process Monitoring

Next, process upscaling in stirred tank bioreactors was performed, firstly in 150-mL (DASbox) and subsequently in up to 500-mL culture scale in a larger system (Bioblock). Applying the protocol in Figure 5A the cell density was adjusted to 0.5 × 10⁶ cells/mL before induction of differentiation to consider the impact of the bulk cell density and interprocess reproducibility (Kempf et al., 2016).

Growth kinetics revealed that the cell density peaked at >1.5 × 10⁶ cells/mL on days 3–5 but declined thereafter, resulting in 1 ± 0.1 × 10⁶ total cells/mL on day 10 corresponding to 0.93 ± 0.1 × 10⁶ CMs/mL (Figures 5B and S4B), thus yielding ~130 × 10⁶ CMs per run in 150-mL scale.

On day 10, FC revealed a CM content of 93.5% ± 5.0%, 94.13% ± 2.8%, and 92.9% ± 3.64% for cTNT, MHC, and SA, respectively (Figures 5C and S4A), demonstrating high process efficiency and reproducibility.

This endpoint analysis for CM markers was correlated to CD13+/ROR1+ on day 3 for a large number of experiments across the entire optimization phase, including preliminary conditions leading to low CM contents (Figure 5D). The observed correlation coefficient of r = 0.63 may not seem ideal but the following must be considered: (1) the biological variance inherent to such complex biological systems, in particular when correlating two time points being 7 days apart; and (2) the transient nature of the CD13+/ROR1+ expression whereby slight variations in
process timing and analysis may substantially impact on this correlation. With this in mind, the plot in Figure 5D highlights that the presence of low, i.e., ~20%–40% of CD13+/ROR1+ cells, on day 3 is a strong hint for low CM content, typically <30% on day 10. In contrast, measurement of ~60%–80% of CD13+/ROR1+ cells on day 3 typically resulted in 80%–98% CMs. As exemplarily depicted by inset pictures in the schematic (Figure 5A), the average cell aggregate diameter changed along bioreactor-based processes, rising from 112.8 ± 34.5 μm (day 0) to 214.5 ± 66.8 μm (day 10; Figure S4D). Moreover, online monitoring of pH and DO revealed typical “zigzag” curves between individual medium changes (Figure S4C). After day 3, the pH drop pattern was flatter in line with both decreasing cell numbers and the expected switch from a highly glycolytic metabolism established for the pluripotent state (Cliff et al., 2017; Moussaieff et al., 2015) toward more oxidative phosphorylation (and thus reduced lactate production) in differentiating cells. This was confirmed by glucose/lactate assessment (Figure S4E) for specific yield coefficient (Y) calculation, which was highest during the first days of differentiation and dropped strongly between days 2 and 5 (Figure S4F).

We next performed a proof of concept for up to 3-fold process upscaling, i.e., from 150- toward 500-mL scale in a larger stirred tank reactor system (Bioblock) revealing high similarity for key parameters including growth kinetics, cell yields, and CM content, whereas a somewhat smaller mean aggregate diameter was observed at a larger scale (Figure 5F). The green bars in Figure 5C show that 89.13% ± 7.8%, 90.53% ± 6.7%, and 92.03% ± 4.4% of cTnT-, SA-, and MHC-expressing CMs, respectively, were observed on day 10. The cell density was 1.05 ± 0.19 × 10^6 cells/mL (green line in Figure 5B). Together these data demonstrate platform- and process-scale-independent robustness.

**Qualitative Analysis Reveals High Purity of Functional Ventricular Cardiomyocytes**

Assessing CMs’ electrophysiological properties revealed 70 out of 73 action potentials (APs) with long plateau phase...
and steep phase-3 repolarization (physiological APs found at 37°C; Figures 6A, 6B, SSA, and SSB), reflecting a ventricular-like phenotype with only three deviating APs noted in three independent differentiations (Figures 6A, 6B, S5A, and S5C–S5E).

For intracellular calcium transients and unloaded twitch contraction recordings (Figures 6C and 6D), plated CMs were electrically stimulated (Mutig et al., 2013). The averaged diastolic calcium ratio at 0.5 Hz (Figure 6C) was 0.8 ± 0.15 and thus higher than 0.6 ± 0.1 previously found...
in hESC-CMs (Mutig et al., 2013; Weber et al., 2016), indicating a possibly lower activity of sarcoplasmic/ endoplasmic calcium reticulum ATPase and Na+/Ca2+ exchanger in hiPSC-CMs in this study. This may be due to the shorter maturation time in culture (i.e., days 14–19 here versus day 35 in Weber et al., 2016). At both electrical stimulation frequencies, systolic calcium ratios (Figure 6C) were higher compared with (Weber et al., 2016) but the amplitude of calcium release (calculated as systolic peak/diastolic ratio) at 0.5 Hz was only slightly elevated (0.26 ± 0.18 versus 0.25 ± 0.1 in Weber et al., 2016). Time to peak and half relaxation times (Figure 6D) of twitch contractions were similar to historical data (Weber et al., 2016).

Notably, only 22% of all measured CMs were spontaneously contracting in the pacing-free interval of the acquisition protocol (Figure S6F). This is ~16% less than previously noted in hESC-CMs using the same analysis (Weber et al., 2016), indicating that (without applying explicit maturation) we here derived CMs exhibiting a less contractile, more ventricular-like phenotype, a property of working myocardium.

Moreover, prolonged cultivation of CM aggregates in 3D resulted in progressively increasing expressions of ventricular myosin light chain 2 (MLC2, Figures S6I and S6J) as indicated for prolonged cultivation of seeded CMs in 2D (Burridge et al., 2014; Lian et al., 2012).

Upon electrically evoked and spontaneous twitch contractions (Figures 6E and S6C–S6E), isoproterenol slightly increased the contraction amplitude and marked shortening of time to peak and half relaxation times (expected positive inotropic and lusitropic effects, Figures S6D and S6E), and a significant increase of the beating frequency of spontaneously contracting CMs from 48.8 ± 3.26 to 68.4 ± 4.4 beats/min (expected positive chronotropic adrenergic effects; Figures S6F and S6G). Moreover, endothelin-1 treatment for 24 h induced a typical increase in cell surface area of plated CMs (Carlson et al., 2013; Figures S6A and S6B).

Finally, our resulting CMs were used for bioartificial cardiac tissue (BCT) generation (Kempf et al., 2014; Kensah et al., 2013). After 21 days of cultivation, tissues displayed homogeneous distribution of aligned CMs and synchronized spontaneous beating at 62.8 ± 4.7 beats/min and contraction-relaxation times (tC80%) of 146.1 ± 6.0 and 181.8 ± 8.1 ms, respectively (Figures 6F–6I, S6G, and S6H). In response to increased preload, both spontaneous and electrically paced forces increased significantly to 1.82 ± 0.04 and 1.80 ± 0.04 mN, respectively (Figure 6I). We also observed frequency-dependent acceleration of relaxation: compared with the initial relaxation time at 1 Hz, tR80% was reduced by 28% or 51% at 2 Hz or 3 Hz, respectively (Figures S6G and S6H).

Together, this highlights the typical physiological and mechanical properties of our hPSC-CMs indicating pronounced ventricular-like features.

**DISCUSSION**

Directed cardiac differentiation has been continuously improved over the past decade, progressing toward simpler, more robust, and scalable conditions (Kempf et al., 2014; Lian et al., 2012; Yang et al., 2008). In this study we introduce an integrated, chemically defined differentiation platform enabling the production of human cardiomyocytes in 3D aggregate culture suitable for upscaling in controlled stirred tank bioreactors.

Previous studies demonstrated a substantial impact of preculture conditions (Kempf et al., 2014) at the pluripotent hPSC aggregate stage (Kempf et al., 2014) and the early differentiation phase (Faial et al., 2015; Kempf et al., 2016; Mendjan et al., 2014) on cardiomyogenesis. Culture conditions were revealed that do support an accelerated differentiation progression including efficient PS formation and mesoderm induction, but ultimately failed to direct efficient cardiomyogenesis (Kempf et al., 2014, 2016; Laco et al., 2018; Mendjan et al., 2014).

We hypothesized here that, despite thoroughly directing hPSC priming toward precardiac mesoderm (i.e., by controlling cell aggregation and preculture timing, cell density adaptation ahead of differentiation, exact CHIR dosing, and incubation timing), the “48-h gap” of external WNT pathway control (which is inherent to the previous differentiation protocol, i.e., between CHIR deprivation after 24 h and before IWP addition at 72 h) is prone to perturbing lineage identity. Such perturbation is likely promoted by the complex paracrine environment and multiple signaling pathway activity in hPSCs downstream of CHIR addition (Gaspari et al., 2018; Kempf et al., 2016) and may lead to both a more broad induction of PS-like cell identities and less controlled progression to (posterior) mesoderm fates, i.e., paraxial mesoderm progenies.

We thus considered recent findings on mesoderm specification (Loh et al., 2016) to more stringently control hPSC priming to a defined transition point of lateral mesoderm specification (by meticulously defined preculture and CHIR treatment). This is followed by efficient transition of the entire progenitor population toward cardiac mesoderm (rather than undesired branching toward, e.g., limb bud mesoderm; Loh et al., 2016) by immediate chemical control of WNT pathway inhibition. The success of this immediate CHIR-to-IWP transition strategy is reflected in early gene expression data revealing suppression of CDX2 and MSX1, established inhibitors of

374 Stem Cell Reports | Vol. 13 | 366–379 | August 13, 2019
of cardiac mesoderm formation (Mendjan et al., 2014; Rao et al., 2016).

Opposing the gene expression patterns specific to cardiac mesoderm (resulting from immediate IWP addition on day 1) versus presomitic mesoderm (achieved by the lack of IWP before day 3) allowed us to evaluate several known cardiac/mesodermal progenitor markers including KDR, PDGFRA, SSEA1, NCAM, ROR2, and CD13 (Ardehali et al., 2013; Eyseenko et al., 2010; Kattman et al., 2011; Lee et al., 2017; Nelson et al., 2008; Yang et al., 2008; Yoon et al., 2018) regarding their suitability for early process monitoring and eventually predicting functional CM formation at later stages. Interestingly, none of the established markers was well suited to discriminate early cardiac from presomitic mesoderm. Instead, we identified ROR1 in combination with CD13 (to exclude presence of ROR1-expressing undifferentiated cells; see Figure S2A) as being more informative in distinguishing between cardiac and presomitic mesoderm. This marker combination on day 3 was indeed more prognostic for indicating CM formation at later stages. Interestingly, none of the respective processes (such as preculture duration, aggregate diameter, and inoculation cell density) represents an absolute requirement or a universal process-independent parameter for controlling directed lineage differentiation. These are rather correlative observations, which have to be interpreted within the context of the respective process. Interestingly, the group of Oh recently investigated the proliferative status of hPSCs regarding their impact on the cardiac differentiation efficiency (Laco et al., 2018). Results suggest that monitoring defined molecular markers of cell proliferation may indeed be a more universal, culture platform-independent approach to reassess hPSCs’ compatibility with cardiac differentiation, although additional validation is required.

Regarding process yields, Chen et al. (2015) published ~0.2 million CMs/mL whereas Fonoudi et al. (2015) reported ~0.8 million CMs/mL in their approach (Chen et al., 2015; Fonoudi et al., 2015). We here show the induction of ~1 million CMS/mL in process dimensions from 150 to 500 mL across two bioreactor platforms at increasing dimension, ultimately resulting in the production of up to ~450 × 10^6 CMs in a single process run. Using a non-directed differentiation approach followed by antibiotic selection, Correia et al. (2014) reported the production of 2.3 × 10^6 CMS/mL in WAVE bioreactors with 0.64 × 10^6 in stirred tank bioreactors (Correia et al., 2014). In another concept applying microcarriers, Ting et al. (2014) generated up to 1.6 × 10^6 CMS/mL. A meaningful cross-comparison of these studies is problematic, given the great heterogeneity of bioreactor platforms and the overall experimental environment. Importantly, our protocol described here is one of the first demonstrating chemically defined conditions in scalable suspension culture inducing a high CM content of >90%.

Notably, functional characterization by numerous complementary methods revealed a predominantly ventricular-like CMs phenotype, which may support in vitro disease modeling and pharmacological assays as well as envisioned regenerative therapies of heart repair (Liu et al., 2018).

**EXPERIMENTAL PROCEDURES**

For standard methods and prepublished techniques, please refer to Supplemental Experimental Procedures.

**Cell Culture**

The cell lines HES3 (HES3-MIXL1<sup>wt/eGFP</sup>; Davis et al., 2008, HES3-NKX2.5<sup>wt/eGFP</sup>; Elliott et al., 2011), H9, HSC-iPS2
Bioreactor Differentiation in Chemically Defined Conditions

Chemically defined differentiation was performed in Erlenmeyer flasks (20 mL working volume) and in stirred tank bioreactors (working volume: 150 mL/DASbox Mini Bioreactor System or 350–500 mL/Bioblock DASGIP Parallel Bioreactor System) as depicted in Figures 3A and 5A, respectively (Eppendorf). After established inoculation/preculture (Kropp et al., 2016) cell density was determined after 48 h and adjusted to 5 × 10⁵ cells/mL for differentiation in CDM3 (Burridge et al., 2014) supplemented with 5 μM CHIR and 5 μM Y-27632. Precisely 24 h later the medium was replaced by CDM3 plus 5 μM IWP2, and pure CDM3 was added 48 h later and every 2–3 days thereafter. Aggregate diameter, cell density, and metabolites were analyzed as previously published (Kropp et al., 2016).

Statistics

Data are presented as mean ± standard error of the mean. Unless otherwise noted, statistical significance was calculated using Student’s t tests. To take account of multiplicity in group comparisons, one- or two-way ANOVA followed by Bonferroni’s post test were conducted. Statistical significance is denoted by *p < 0.05, **p < 0.01, ***p < 0.001, and ns (not significant) in the figures.

ACCESSION NUMBERS

The microarray data were deposited in the ArrayExpress database under accession number ArrayExpress: E-MTAB-6828.

SUPPLEMENTAL INFORMATION

Supplemental Information can be found online at https://doi.org/10.1016/j.stemcr.2019.06.004.

AUTHOR CONTRIBUTIONS

C.H., H.K., K.S., and R.Z. designed the experiments. C.H., A.F., W.L., M.S., N.W., F.O., j.d.i.R., F.P., S.B., S.W., S.M., K.S., and H.K. performed the experiments. C.H., K.S., M.S., N.W., j.d.i.R., I.G., M.F., H.K., and R.Z. analyzed and interpreted the data. T.K., I.G., M.F., K.W., U.M., and R.Z. provided conceptual advice and financial support. C.H., H.K., N.W., M.F., I.G., and R.Z. wrote the article.

ACKNOWLEDGMENTS

We would like to thank A. Kirschning and G. Dräger for providing Y-27632 and CHIR99021, A. Haase for providing various iPSC lines, S. Malyshева for providing the cell line CDM2_iPS, E. Stanley and A. Elefanty for providing the HES3-NKX2.5 and HES3-MIXL1 cell lines, A. Francino and F. Navarro-Lopez (Hospital Clinic, University of Barcelona, Spain) for providing skin fibroblasts from a patient with hypertrophic cardiomyopathy to generate the cell line bMHC_iPS, and T. Holler and A. Lingk for supporting and performing immunofluorescence. We also thank the RCU Transcriptomics at Hannover Medical School for performing the microarray experiments. R.Z. received funding from the German Research Foundation (DFG; Cluster of Excellence REBIRTH EXC 62/2, ZW64/4-1 as well as KFO311 and ZW64/7-1), German Ministry for Education and Science (BMBF, grants: 13N14086, 01EK1601A, 01EK1602A), StemBANCC (support from the Innovative Medicines Initiative joint undertaking under grant agreement no. 115439-2), resources of which are composed of financial contributions from the European Union’s Seventh Framework Programme (FP7/2007-2013) and EFPIA companies’ kind contribution, and the European Union H2020 program to the project TECHNOBEAT (grant 66724). H.K. received funding from Joachim Herz Stiftung and MHH Hannover (HILF grant). T.K. received funding from the German Research Foundation (DFG TK1187/21-1).

Accepted: June 24, 2019
Published: July 25, 2019

REFERENCES

Abecasis, B., Aguiar, T., Arnauld, E., Costa, R., Gomes-Alves, P., Aspegren, A., Serra, M., and Alves, P.M. (2017). Expansion of 3D human induced pluripotent stem cell aggregates in bioreactors: bioprocess intensification and scaling-up approaches. J. Biotechnol. 246, 81–93.

Ackermann, M., Kempf, H., Hetzel, M., Hesse, C., Hashtchin, A.R., Brinkert, K., Schott, J.W., Haake, K., Kuhnle, M.P., Glage, S., et al. (2018). Bioreactor-based mass production of human iPSC-derived macrophages enables immunotherapies against bacterial airway infections. Nat. Commun. 9, 5088.

Alev, C., Wu, Y., Kasukawa, T., Jakt, L.M., Ueda, H.R., and Sheng, G. (2010). Transcriptomic landscape of the primitive streak. Development 137, 2863–2874.

Ardehali, R., Ali, S.R., Inlay, M.A., Abilez, O.J., Chen, M.Q., Bluw-kamp, T.A., Yazawa, M., Gong, Y., Nusse, R., Drukker, M., et al. (2013). Prospective isolation of human embryonic stem cell-derived
cardiovascular progenitors that integrate into human fetal heart tissue. Proc. Natl. Acad. Sci. U S A 110, 3405–3410.

Bargaje, R., Trachana, K., Shelton, M.N., McGinnis, C.S., Zhou, J.X., Chadick, C., Cook, S., Cavanaugh, C., Huang, S., and Hood, L. (2017). Cell population structure prior to bifurcation predicts efficiency of directed differentiation in human induced pluripotent cells. Proc. Natl. Acad. Sci. U S A 114, 2271–2276.

Biben, C., Hatzistavrou, T., and Harvey, R.P. (1998). Expression of NK-2 class homeobox gene Nkx2-6 in foregut endoderm and heart. Mech. Dev. 73, 125–127.

Burridge, P.W., Matsa, E., Shukla, P., Lin, Z.C., Churko, J.M., Ebert, A.D., Lan, F., Diecke, S., Huber, B., Mordwinkin, N.M., et al. (2014). Chemically defined generation of human cardiomyocytes. Nat. Methods 11, 855–860.

Carlson, C., Koonce, C., Aoyama, N., Einhorn, S., Fiene, S., Thompson, A., Swanson, B., Anson, B., and Kattman, S. (2013). Phenotypic screening with human iPSC cell-derived cardiomyocytes: HTS-compatible assays for interrogating cardiac hypertrophy. J. Biomol. Screen. 18, 1203–1211.

Chen, V.C., Couture, S.M., Ye, J., Lin, Z., Hua, G., Huang, H.I., Wu, J., Hsu, D., Carpenter, M.K., and Couture, L.A. (2012). Scalable GMP compliant suspension culture system for human ES cells. Stem Cell Res. 8, 388–402.

Chen, V.C., Ye, J., Shukla, P., Hua, G., Chen, D., Lin, Z., Liu, J.C., Chai, J., Gold, J., Wu, J., et al. (2015). Development of a scalable suspension culture for cardiac differentiation from human pluripotent stem cells. Stem Cell Res. 15, 365–375.

Christoffersson, J., Meier, F., Kempf, H., Schwanke, K., Coffee, M., Beilmann, M., Zweigerdt, R., and Mandenius, C.F. (2018). A cardiac cell outgrowth assay for evaluating drug compounds using a cardiac spheroid-on-a-chip device. Bioengineering (Basel) 5. https://doi.org/10.3390/bioengineering5020036.

Cliff, T.S., Wu, T., Boward, B.R., Yin, A., Yin, H., Glushka, J.N., Prestegaard, J.H., and Dalton, S. (2017). MYC controls human pluripotent stem cell fate decisions through regulation of metabolic flux. Cell Stem Cell 21, 502–516.e9.

Correia, C., Serra, M., Espirinha, N., Sousa, M., Brito, C., Burkert, K., Zheng, Y., Hescheler, J., Carrondo, M.J., Saric, T., et al. (2014). Combining hypoxia and bioreactor hydrodynamics boosts induced pluripotent stem cell differentiation towards cardiomyocytes. Stem Cell Rev. 10, 786–801.

Davis, R.P., Ng, E.S., Costa, M., Mossman, A.K., Sourris, K., Elefanty, A.G., and Stanley, E.G. (2008). Targeting a GFP reporter gene to the MIXL1 locus of human embryonic stem cells identifies human primitive streak-like cells and enables isolation of primitive hematopoietic precursors. Blood 111, 1876–1884.

Devalia, H.D., Schwach, V., Ford, J.W., Milnes, J.T., El-Haou, S., Jackson, C., Gkatzis, K., Elliott, D.A., Chua de Sousa Lopes, S.M., Mummery, C.L., et al. (2015). Atrial-like cardiomyocytes from human pluripotent stem cells are a robust preclinical model for assessing atrial-selective pharmacology. EMBO Mol. Med. 7, 394–410.

Elliott, D.A., Braam, S.R., Koutsis, K., Ng, E.S., Jenny, R., Lagerqvist, E.L., Biben, C., Hatzistavrou, T., Hirst, C.E., Yu, Q.C., et al. (2011). NKX2-5(eGFP/w) hESCs for isolation of human cardiac progenitors and cardiomyocytes. Nat. Methods 8, 1037–1040.

Evseenko, D., Zhu, Y., Schenke-Layland, K., Kuo, J., Latour, B., Ge, S., Scholes, J., Dravid, G., Li, X., MacLellan, W.R., et al. (2010). Mapping the first stages of mesoderm commitment during differentiation of human embryonic stem cells. Proc. Natl. Acad. Sci. U S A 107, 13742–13747.

Faial, T., Bernardo, A.S., Mendjan, S., Diamanti, E., Ortmann, D., Gentsch, G.E., Mascetti, V.L., Trotter, M.W., Smith, J.C., and Pedersen, R.A. (2015). Brachyury and SMAD signalling collaboratively orchestrate distinct mesoderm and endoderm gene regulatory networks in differentiating human embryonic stem cells. Development 142, 2121–2135.

Fonoudi, H., Ansari, H., Abbasalizadeh, S., Larjiani, M.R., Kiani, S., Hashemizadeh, S., Zarchi, A.S., Bosman, A., Blue, G.M., Pahlavan, S., et al. (2015). A universal and robust integrated platform for the scalable production of human cardiomyocytes from pluripotent stem cells. Stem Cells Transl. Med. 4, 1482–1494.

Gaspari, E., Franke, A., Robles-Diaz, D., Zweigerdt, R., Roeder, L., Zerujatke, T., and Kempf, H. (2018). Paracrine mechanisms in early differentiation of human pluripotent stem cells: insights from a mathematical model. Stem Cell Res. 32, 1–7.

Gonzalez, R., Lee, J.W., and Schultz, P.G. (2011). Stepwise chemically induced cardiomyocyte specification of human embryonic stem cells. Angew. Chem. 50, 11181–11185.

Greber, B., Wu, G., Bernemann, C., Joo, J.Y., Han, D.W., Ko, K., Tapia, N., Sabour, D., Sternebeck, J., and Tesar, P. (2010). Conserved and divergent roles of IGF signaling in mouse epiblast stem cells and human embryonic stem cells. Cell Stem Cell 6, 215–226.

Grunolato, L., Liu, G., Mong, P., Mudbhary, R., Biswas, R., Arroyave, R., Vijayakumar, S., Economides, A.N., and Aaronson, S.A. (2010). Canonical and noncanonical Wnts use a common mechanism to activate completely unrelated coreceptors. Genes Dev. 24, 2517–2530.

Haae, A., Gohring, G., and Martin, U. (2017). Generation of transgenic iPSC cells from human cord blood CD34+(+ cells under animal component-free conditions. Stem Cell Res. 21, 71–73.

Haae, A., Olmer, R., Schwanke, K., Wunderlich, S., Merkert, S., Hess, C., Zweigerdt, R., Gruh, I., Meyer, J., Wagner, S., et al. (2009). Generation of induced pluripotent stem cells from human cord blood. Cell Stem Cell 5, 434–441.

Hartung, S., Schwanke, K., Haae, A., David, R., Franz, W.M., Martin, U., and Zweigerdt, R. (2013). Directing cardiomyogenic differentiation of human pluripotent stem cells by plasmid-based transient overexpression of cardiac transcription factors. Stem Cell Dev. 22, 1112–1125.

Ho, H.Y., Susman, M.W., Bikoff, J.B., Ryu, Y.K., Jonas, A.M., Hu, L., Kuruviella, R., and Greenberg, M.E. (2012). Wnt5a-Ror-Dishollow signalling constitutes a core developmental pathway that controls tissue morphogenesis. Proc. Natl. Acad. Sci. U S A 109, 4044–4051.

Kattman, S.J., Witty, A.D., Faglardi, M., Dubois, N.C., Napour, M., Hotta, A., Ellis, J., and Keller, G. (2011). Stage-specific optimization of activin/nodal and BMP signalling promotes cardiac differentiation of mouse and human pluripotent stem cells. Cell Stem Cell 8, 228–240.
Kempf, H., Kropp, C., Olmer, R., Martin, U., and Zweigerdt, R. (2015). Cardiac differentiation of human pluripotent stem cells in scalable suspension culture. Nat. Protoc. 10, 1345–1361.

Kempf, H., Olmer, R., Haase, A., Franke, A., Bolesani, E., Schwanken K., Robles-Diaz, D., Coffee, M., Gohring, G., Drager, G., et al. (2016). Bulk cell density and Wnt/TGFbeta signalling regulate mesendodermal patterning of human pluripotent stem cells. Nat. Commun. 7, 13602.

Kempf, H., Olmer, R., Kropp, C., Ruckert, M., Jara-Avaca, M., Robles-Diaz, D., Franke, A., Elliott, D.A., Wojciechowski, D., Fischer, M., et al. (2014). Controlling expansion and cardiomyogenic differentiation of human pluripotent stem cells in scalable suspension culture. Stem Cell Rep. 3, 1132–1146.

Kensah, G., Roa Lara, A., Dahlmann, J., Zweigerdt, R., Schwanken K., Hegermann, J., Skvorc, D., Gawol, A., Azizian, A., Wagner, S., et al. (2013). Murine and human pluripotent stem cell-derived cardiac bodies form contractile myocardial tissue in vitro. Eur. Heart J. 34, 1134–1146.

Kim, M.S., Pinto, S.M., Getnet, D., Nirujoyi, R.S., Manda, S.S., Chaerkady, R., Madugundu, A.K., Kelkar, D.S., Isserlin, R., Jain, S., et al. (2014). A draft map of the human proteome. Nature 509, 575–581.

Kinder, S.J., Tsang, T.E., Quinlan, G.A., Hadjantonakis, A.K., Nagy, A., and Tam, P.P. (1999). The orderly allocation of mesodermal cells to the extraembryonic structures and the anteroposterior axis during gastrulation of the mouse embryo. Development 126, 4691–4701.

Kropp, C., Kempf, H., Halloin, C., Robles-Diaz, D., Franke, A., Scheper, T., Kinast, K., Knorpp, T., Joos, T.O., Haverich, A., et al. (2016). Impact of feeding strategies on the scalable expansion of human pluripotent stem cells in single-use stirred tank bioreactors. Stem Cells Transl. Med. 5, 1289–1301.

Laco, E., Woo, T.I., Zhong, Q., Szymy, R., Ting, S., Khan, E.J., Chai, C.L.L., Revenuy, S., Chen, A., and Oh, S. (2018). Unraveling the inconsistencies of cardiac differentiation efficiency induced by the GSK3beta inhibitor CHIR99021 in human pluripotent stem cells. Stem Cell Rep. 10, 1851–1866.

Lee, J.H., Protze, S.I., Laksman, Z., Backx, P.H., and Keller, G.M. (2017). Human pluripotent stem cell-derived atrial and ventricular cardiomyocytes develop from distinct mesoderm populations. Cell Stem Cell 21, 179–194.e4.

Lian, X., Hsiao, C., Wilson, G., Zhu, K., Hazeltine, L.B., Azarin, S.M., Raval, K.K., Zhang, J., Kamp, T.J., and Palecek, S.P. (2012). Robust cardiomyocyte differentiation from human pluripotent stem cells via temporal modulation of canonical Wnt signaling. Proc. Natl. Acad. Sci. U S A 109, E1848–E1857.

Liu, Y.W., Chen, B., Yang, X., Fugate, J.A., Kalucki, F.A., Futakuchi-Tsuchida, A., Couture, L., Vogel, K.W., Astley, C.A., Baldessari, A., et al. (2018). Human embryonic stem cell-derived cardiomyocytes restore function in infarcted hearts of non-human primates. Nat. Biotechnol. 36, 597–605.

Loh, K.M., Chen, A., Koh, P.W., Deng, T.Z., Sinha, R., Tsai, J.M., Barkal, A.A., Shen, K.Y., Jain, R., Morganti, R.M., et al. (2016). Mapping the pairwise choices leading from pluripotency to human bone, heart, and other mesoderm cell types. Cell 166, 451–467.

Ludwig, T.E., Bergendahl, V., Levenstein, M.E., Yu, J., Probasco, M.D., and Thomson, J.A. (2006). Feeder-independent culture of human embryonic stem cells. Nat. Methods 3, 637–646.

Malysheva, S.V., Wunderlich, S., Haase, A., Gohring, G., Martin, U., and Merkert, S. (2018). Generation of a human CDX2 knockout reporter iPSC line (MHHi007-A-1) to model human trophoblast differentiation. Stem Cell Res. 30, 117–121.

Matsuda, T., Nomi, M., Ikeya, M., Kani, S., Oishi, I., Terashima, T., Takada, S., and Minami, Y. (2001). Expression of the receptor tyrosine kinase genes, Ror1 and Ror2, during mouse development. Mech. Dev. 105, 153–156.

Mendjan, S., Mascetti, V.L., Ortmann, D., Ortiz, M., Karjusokaru, D.W., Ng, Y., Moreau, T., and Pedersen, R.A. (2014). NANOG and CDX2 pattern distinct subtypes of human mesoderm during exit from pluripotency. Cell Stem Cell 15, 310–325.

Moussaieff, A., Rouleau, M., Kitsberg, D., Cohen, M., Levy, G., Barash, D., Nemirovski, A., Shen-Orr, S., Laevsky, I., Amit, M., et al. (2015). Glycolysis-mediated changes in acetyl-CoA and histone acetylation control the early differentiation of embryonic stem cells. Cell Metab. 21, 392–402.

Muitig, N., Geers-Knoerr, C., Piep, B., Pahuja, A., Vogt, P.M., Brenner, B., Niederbichler, A.D., and Kraft, T. (2013). Lipoteichoic acid from Staphylococcus aureus directly affects cardiomyocyte contractility and calcium transients. Mol. Immunol. 56, 720–728.

Nelson, T.J., Faustino, R.S., Chiriac, A., Crespo-Diaz, R., Behfar, A., and Terzic, A. (2008). CXCR4+/FLK-1+ biomarkers select a cardio-poietic lineage from embryonic stem cells. Stem Cells 26, 1464–1473.

Olmer, R., Engels, L., Usman, A., Menke, S., Malik, M.N.H., Pessler, F., Gohring, G., Bornhorst, D., Bolten, S., Abdelilah-Seyfried, S., et al. (2018). Differentiation of human pluripotent stem cells into functional endothelial cells in scalable suspension culture. Stem Cell Rep. 10, 1657–1672.

Olmer, R., Lange, A., Selzer, S., Kasper, C., Haverich, A., Martin, U., and Zweigerdt, R. (2012). Suspension culture of human pluripotent stem cells in controlled, stirred bioreactors. Tissue engineering part C. Methods 18, 772–784.

Palecek, J., Zweigerdt, R., Olmer, R., Martin, U., Kirschning, A., and Drager, G. (2011). A practical synthesis of Rho-Kinase inhibitor Y-27632 and fluoro derivatives and their evaluation in human pluripotent stem cells. Org. Biomol. Chem. 9, 5503–5510.

Peng, G., Suo, S., Chen, J., Chen, W., Liu, C., Yu, F., Wang, R., Chen, S., Sun, N., Cui, G., et al. (2016). Spatial transcriptome for the molecular annotation of lineage fates and cell identity in mid-gastrula mouse embryo. Dev. Cell 36, 681–697.

Protze, S.I., Liu, J., Nussinovitch, U., Ohana, L., Backx, P.H., Gepstein, L., and Keller, G.M. (2017). Sinoatrial node cardiomyocytes derived from human pluripotent cells function as a biological pacemaker. Nat. Biotechnol. 35, 56–68.

Rao, J., Pfeiffer, M.J., Frank, S., Adachi, K., Piccini, I., Quaranta, R., Arauzo-Bravo, M., Schwarz, J., Schade, D., Leidel, S., et al. (2016). Stepwise clearance of repressive roadblocks drives cardiac induction in human ESCs. Cell Stem Cell 18, 341–353.

Shelton, M., Metz, J., Liu, J., Carpenedo, R.L., Demers, S.P., Stanford, W.L., and Skerjanc, I.S. (2014). Derivation and expansion of...
PAX7-positive muscle progenitors from human and mouse embryonic stem cells. Stem Cell Rep. 3, 516–529.
Siller, R., Greenhough, S., Naumovska, E., and Sullivan, G.J. (2015). Small-molecule-driven hepatocyte differentiation of human pluripotent stem cells. Stem Cell Rep. 4, 939–952.
Silva, M.M., Rodrigues, A.F., Correia, C., Sousa, M.F., Brito, C., Corroadinha, A.S., Serra, M., and Alves, P.M. (2015). Robust expansion of human pluripotent stem cells: integration of bioprocess design with transcriptomic and metabolomic characterization. Stem Cells Transl. Med. 4, 731–742.
Skelton, R.J.P., Kamp, T.J., Elliott, D.A., and Ardehali, R. (2017). Biomarkers of human pluripotent stem cell-derived cardiac lineages. Trends Mol. Med. 23, 651–668.
Soh, B.S., Ng, S.Y., Wu, H., Buac, K., Park, J.H., Lian, X., Xu, J., Foo, K.S., Feldin, U., He, X., et al. (2016). Endothelin-1 supports clonal derivation and expansion of cardiovascular progenitors derived from human embryonic stem cells. Nat. Commun. 7, 10774.
Ting, S., Chen, A., Reuveny, S., and Oh, S. (2014). An intermittent rocking platform for integrated expansion and differentiation of human pluripotent stem cells to cardiomyocytes in suspended microcarrier cultures. Stem Cell Res. 13, 202–213.
Tran, T.H., Wang, X., Browne, C., Zhang, Y., Schinke, M., Izumo, S., and Burcin, M. (2009). Wnt3a-induced mesoderm formation and cardiomyogenesis in human embryonic stem cells. Stem Cells 27, 1869–1878.
Ueno, S., Weidinger, G., Osugi, T., Kohn, A.D., Golob, J.L., Pabon, L., Reinecke, H., Moon, R.T., and Murry, C.E. (2007). Biphasic role for Wnt/beta-catenin signaling in cardiac specification in zebrafish and embryonic stem cells. Proc. Natl. Acad. Sci. U S A 104, 9685–9690.
Wattanapanitch, M., Klinicmmhom, N., Potirat, P., Amornpisutt, R., Lorthongpanich, C., U-pratya, Y., Laowtammahtron, C., Kheolamai, P., Pongvarin, N., and Issaragrisil, S. (2014). Dual small-molecule targeting of SMAD signaling stimulates human induced pluripotent stem cells toward neural lineages. PLoS One 9, e106952.
Weber, N., Schwanke, K., Greten, S., Wendland, M., Iorga, B., Fischer, M., Geers-Knorr, C., Hegemann, J., Wrede, C., Fiedler, J., et al. (2016). Stiff matrix induces switch to pure beta-cardiac myosin heavy chain expression in human ESC-derived cardiomyocytes. Basic Res. Cardiol. 111, 68.
Yang, L., Soonpaa, M.H., Adler, E.D., Roepke, T.K., Kattman, S.J., Kennedy, M., Henckaerts, E., Bonham, K., Abbott, G.W., Linden, R.M., et al. (2008). Human cardiovascular progenitor cells develop from a KDR+ embryonic-stem-cell-derived population. Nature 453, 524–528.
Yoon, C., Song, H., Yin, T., Bausch-Fluck, D., Frei, A.P., Kattman, S., Dubois, N., Witty, A.D., Hewel, J.A., Guo, H., et al. (2018). FZD4 marks lateral plate mesoderm and signals with NORRIN to increase cardiomyocyte induction from pluripotent stem cell-derived cardiac progenitors. Stem Cell Rep. 10, 87–100.